Blood Collection Tubes for Liquid Biopsy Market Size, Share, and Forecast to 2035

The global Blood Collection Tubes for Liquid Biopsy Market is experiencing robust growth, with an estimated valuation of USD 74.5 million in 2025, projected to reach USD 285.4 million by 2035, reflecting a compound annual growth rate (CAGR) of 14.1%. This expansion is driven by the increasing adoption of liquid biopsy as a non-invasive diagnostic tool, rising prevalence of cancer, and advancements in precision medicine. The market is further propelled by technological innovations in blood collection tubes, such as those designed to stabilize circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), alongside growing demand for early cancer detection and personalized treatment strategies.

The significance of this market lies in its transformative impact on cancer diagnostics and monitoring. Liquid biopsy, facilitated by specialized blood collection tubes, enables the analysis of biomarkers like ctDNA, cfRNA, and CTCs from blood samples, offering a less invasive alternative to traditional tissue biopsies. With approximately 20 million new cancer cases globally in 2022, as reported by the World Cancer Research Fund International, the need for reliable, non-invasive diagnostic methods is critical. These tubes play a pivotal role in supporting early detection, treatment monitoring, and personalized medicine, improving patient outcomes and reducing healthcare burdens.

For more insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4495

Market Analysis

The blood collection tubes for liquid biopsy market is driven by the global surge in cancer incidence, advancements in diagnostic technologies, and the shift toward precision medicine. Liquid biopsy’s ability to detect tumor-specific aberrations in ctDNA and CTCs supports early diagnosis and real-time monitoring, particularly for cancers like breast, lung, and prostate. The market benefits from increased healthcare expenditure, favorable reimbursement policies, and growing adoption of next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays. North America, with its advanced healthcare infrastructure, leads the market, while Asia Pacific is emerging as a high-growth region due to rising cancer awareness and healthcare investments.

Challenges include the lack of skilled professionals to handle advanced diagnostic techniques, which can hinder market growth in developing regions. High costs of specialized tubes and liquid biopsy procedures may limit adoption in low-resource settings. Additionally, regulatory hurdles and the need for standardized protocols for biomarker preservation pose barriers. However, ongoing R&D, strategic collaborations, and regulatory support for innovative diagnostics are expected to mitigate these challenges and drive market expansion.

Segment Analysis

The market is segmented by product, material, application, and end-user. By product, ccfDNA/cfDNA tubes dominate due to their widespread use in detecting circulating cell-free DNA for cancer diagnostics, holding the largest share in 2025. CTC tubes are gaining traction for their role in monitoring metastatic potential. By material, plastic tubes lead with over 70% market share, valued for their cost-effectiveness, durability, and reduced contamination risk, while glass tubes are preferred in specific high-precision applications. By application, in-vitro diagnostics (IVD) accounts for over 70% of the market, driven by clinical demand for early cancer detection, followed by research applications for biomarker discovery. By end-user, genetic diagnostic labs are the primary segment, followed by research institutes and hospitals, reflecting the growing integration of liquid biopsy in clinical and research settings.

Country-wise Insights

In the United States, the market is valued at approximately USD 41.1 million in 2025, with a projected CAGR of 13.8% through 2035, driven by a high cancer incidence (2 million new cases in 2024, per the National Cancer Institute) and robust diagnostic infrastructure. The U.S. benefits from FDA approvals, such as Agilent’s ctDx FIRST in 2022, and significant R&D investments. In the United Kingdom, the market is expected to grow at a CAGR of 12.5%, reaching USD 22.3 million by 2035, supported by government initiatives for early cancer detection. In India, the market is projected to reach USD 18.6 million by 2035 (CAGR 15.2%), fueled by rising cancer cases (1.46 million in 2022, per ICMR) and increasing adoption of non-invasive diagnostics.

Key Players

  • Roche
  • Streck, Inc.
  • PreAnalytix GmbH
  • Norgen Biotek Corp.
  • Biocept, Inc.
  • Greiner Bio-One
  • Qiagen

Strategic Outlook and Industry Trends

The market is evolving with technological advancements and a focus on precision diagnostics. Innovations in tube design, such as enhanced stabilization for ctDNA and cfRNA, improve diagnostic accuracy. The integration of liquid biopsy with NGS and AI-driven analytics is a key trend, enabling comprehensive genomic profiling. The expansion of liquid biopsy applications beyond oncology, into areas like infectious diseases and prenatal screening, is creating new opportunities. Strategic collaborations, such as Biodesix and Streck’s 2020 regulatory agreement, and product launches, like Illumina’s TruSight Oncology 500 ctDNA v2 in 2023, are driving market growth. Sustainability efforts, including recyclable plastic tubes, are gaining traction. To remain competitive, companies must invest in R&D, address skill shortages, and navigate regulatory complexities while expanding into emerging markets.

Segmentation of Blood Collection Tubes for Liquid Biopsy Market

  • By Product:
    • ccfDNA/cfDNA Tubes
    • cfRNA Tubes
    • CTC Tubes
    • gDNA Tubes
    • Intracellular RNA Tubes
    • Others
  • By Material:
    • Plastic
    • Glass
  • By Application:
    • In-Vitro Diagnostics (IVD)
    • Research
  • By End-User:
    • Genetic Diagnostic Labs
    • Research Institutes
    • Hospitals
    • Conventional Diagnostic Centers
    • Others
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

Contact

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com

 

 

Comments

Post a Comment

Popular posts from this blog

Novel Drug Delivery Systems (NDDS) Market Size, Share, Growth, Trends, and Forecast 2025-2035

The global   Novel Drug Delivery Systems (NDDS) Market   is set for substantial growth, valued at USD 89.7 billion in 2025 and projected to reach USD 172.9 billion by 2035, registering a compound annual growth rate (CAGR) of 6.8%. This growth is fueled by the rising demand for targeted, effective, and minimally invasive treatments for chronic diseases, oncology, and personalized medicine. The increasing focus on optimizing drug bioavailability, enhancing patient compliance, and minimizing side effects is revolutionizing drug delivery and formulation. NDDS encompasses advanced platforms such as transdermal patches, inhalers, liposomes, nanoparticles, implantable pumps, and microneedle systems, transforming therapeutic outcomes across various medical fields. The significance of this market lies in its ability to address critical challenges in traditional pharmacotherapy. With chronic diseases like cancer, diabetes, and cardiovascular conditions affecting millions globally—14.1 m...
Read more

Venous Procedure Devices Market Size, Share & Growth Outlook to 2035

The global   Venous Procedure Devices Market   is valued at approximately USD 2.2 billion in 2025 and is projected to surpass USD 4.1 billion by 2035, expanding at a compound annual growth rate (CAGR) of 6.4%. This growth is driven by the rising prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, and technological advancements in devices such as stents and catheters. The market is critical for addressing vascular conditions like deep vein thrombosis (DVT) and peripheral arterial disease (PAD), which affect millions globally, with the CDC estimating 900,000 annual DVT cases in the U.S. alone. The shift toward less invasive treatments and the growing adoption of advanced diagnostic tools are further propelling market expansion. The significance of this market lies in its role in improving patient outcomes through innovative devices that enable precise diagnostics and treatments. Venous procedure devices, including catheters, stents, and gu...
Read more

Central Venous Catheters (CVCs) Market Size, Growth Opportunities, and Forecast to 2035

The global   Central Venous Catheters (CVCs) Market   is on a steady growth path, valued at USD 1.5 billion in 2025 and projected to reach USD 2.7 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.0%. This growth is fueled by the rising prevalence of chronic diseases such as cancer and kidney failure, increasing surgical procedures, and advancements in catheter technology. Central venous catheters are critical medical devices used for administering medications, fluids, nutrients, and monitoring hemodynamic status in critical care, oncology, and long-term treatment settings. The market’s expansion is further supported by the growing geriatric population and the increasing demand for minimally invasive procedures. The significance of this market lies in its essential role in modern healthcare, particularly for patients requiring long-term intravenous access. With an estimated 19.3 million new cancer cases globally in 2020 and chronic kidney disease affecting ...
Read more